Form 4: Director John D. Quisel Receives Gossamer Bio Stock Options

Gossamer Bio director John D. Quisel was granted 115,000 stock options as part of the company's non-employee director compensation program.

Summary

• Director John D. Quisel received a grant of 115,000 stock options on June 4, 2026.
• The options have an exercise price of $0.178 per share.
• The grant was issued under the company's established Non-Employee Director Compensation Program.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future performance of Gossamer Bio's common stock price.

Future Outlook

The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with long-term corporate growth.

Comparison to Industry Standards

• The use of annual equity grants for board members is consistent with standard corporate governance practices for publicly traded biotech companies.
• Vesting schedules tied to annual meetings or one-year anniversaries are typical for director compensation packages.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for existing shareholders.

Next Steps

• Vesting of options on the earlier of June 4, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Gossamer Bio, GOSS, Form 4, Director Compensation, Stock Options, Insider Transaction